



# ASTRAZENECA PLC

## PROFIT AND LOSS ACCOUNT

for six months to 30 June 2000

	Notes	Six months to 30 June \$m	Year ended 31 Dec 1999 \$m
Turnover		-	-
Operating costs		-	(7)
<b>Operating loss</b>		-	(7)
Income from shares in subsidiary undertakings		1,250	2,034
Merger costs		10	(70)
<b>Profit on ordinary activities before interest</b>		<b>1,260</b>	<b>1,957</b>
Net interest receivable	2	(202)	(68)
<b>Profit on ordinary activities before taxation</b>		<b>1,058</b>	<b>1,889</b>
Taxation		-	-
<b>Net profit for the period/year</b>		<b>1,058</b>	<b>1,889</b>
Dividends to Shareholders		-	(1,609)
<b>Profit retained for the period/year</b>		<b>1,058</b>	<b>280</b>

## STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

for six months to 30 June 2000

	Notes	Six months to 30 June \$m	Year ended 31 Dec 1999 \$m
Net profit for the period/year		1,058	1,889
Unrealised gain on transfer of investment in Astra AB		-	32,839
Exchange (loss)/gain on receivable arising on transfer of investment in Astra AB		(2,042)	79
<b>Total recognised gains and losses relating to the period/year</b>		<b>(984)</b>	<b>34,807</b>

# ASTRAZENECA PLC

## BALANCE SHEET


at 30 June

	Notes	30 June 2000 \$m	31 Dec 1999 \$m
<b>Fixed assets</b>			
Tangible fixed assets		-	-
Fixed asset investments	4	905	905
		905	905
<b>Current assets</b>			
Stocks		-	-
Debtors		36,872	37,957
Cash and short-term investments		-	-
		36,872	37,957
<b>Total assets</b>		37,777	38,862
<b>Creditors due within one year</b>			
Short-term borrowings		-	-
Other creditors		(2,256)	(2,015)
		(2,256)	(2,015)
<b>Net current assets</b>		34,616	35,942
<b>Total assets less current liabilities</b>		35,521	36,847
<b>Creditors due after more than one year</b>			
Loans		(590)	(590)
		(590)	(590)
<b>Provisions for liabilities and charges</b>		-	-
<b>Net assets</b>		34,931	36,257
<b>Capital and reserves</b>			
Called-up share capital	5	441	444
Share premium account	6	213	202
Capital redemption reserve	6	4	1
Other reserves	6	2,239	2,239
Profit and loss account	6	32,034	33,371
<b>Shareholders' funds - equity interests</b>		34,931	36,257

The financial statements on pages 1 to 5 were approved by the Board of Directors on 27 July 2000 and signed on its behalf by:



Tom McKillop  
Director



Jonathan Symonds  
Director

NOTES RELATING TO THE ACCOUNTS

1 Basis of presentation of financial information

The AstraZeneca PLC accounts are presented in accordance with accounting policies set out in the 1999 annual accounts.

2 Net interest payable

	Six months to 30 June 2000 \$m	Year Ended Dec 1999 \$m
<b>Interest payable and similar charges</b>		
Payable to subsidiary undertakings	(21)	(48)
External interest payable	-	-
	(21)	(48)
<b>Interest receivable and similar income</b>		
Receivable from subsidiary undertakings	21	48
Other	(202)	(68)
	(181)	(20)
<b>Net interest (payable)/receivable</b>	(202)	(68)

3 Dividends to Shareholders

	Six months to 30 June 2000 cents per 25c Share	Year Ended Dec 1999 pence per 25c Share	Six months to 30 June 2000 \$m	Year Ended 31 Dec 1999 \$m
Payment of Astra 1998 Final Dividend	-	-	-	359
1st interim	*	23c	-	408
2nd interim/final	-	47c	-	842
	-	70c	-	1,609

\*the first interim dividend for the year to December 2000 will be declared by the Board on 31<sup>st</sup> July 2000

4

	Fixed Asset Investments		
	Shares \$m	Loans \$m	Total \$m
<b>Cost</b>			
At beginning of period	314	591	905
Additions	-	-	-
<b>Net book value at 31 December 1999</b>	314	591	905

# NOTES RELATING TO THE ACCOUNTS (continued)

## 5 Called-up share capital

	Authorised 1999 \$m	Allotted, called-up and fully paid	
		1999 \$m	1998 \$m
Ordinary Shares (\$0.25 each)	444	444	394
Unissued Ordinary Share (\$0.25 each)	156	-	-
Redeemable Preference Shares	-	-	-
	600	444	394

The movements in share capital during the six months can be summarised as follows:

	No of shares (million)	\$m
At beginning of year	1,775	444
Repurchase of shares	(10)	(3)
	1,765	441

## 6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 2000 \$m	Total 1999 \$m
At beginning of period	202	1	2,239	33,371	35,813	2,492
Retained profit for the period	-	-	-	1,058	1,058	280
Issue of shares	11	-	-	-	11	148
Gain on transfer of investment, net of exchange	-	-	-	(2,042)	(2,042)	32,918
Repurchase of shares	-	-	-	(350)	(350)	(182)
Transfer to capital redemption	-	3	-	(3)	-	-
Redenomination of share capital	-	-	-	-	-	182
At end of period	213	4	2,239	32,034	34,490	35,813

In 1999 the Company sold its investment in Astra AB to a subsidiary, resulting in a gain of \$32,839m which was taken to reserves via the statement of total recognised gains and losses. This gain, which represents an unrealised profit, is being realised as the underlying receivable is settled in cash. The unrealised exchange loss on the underlying receivable for the six months ended 30 June 2000 of \$2,042m (year ended 31 December 1999: gain of \$79m) has also been taken to reserves via the statement of total recognised gains and losses. The balance on the profit and loss account at 30 June 2000 includes \$30,876m which is not available for distribution (31 December 1999 - \$32,918m). Included in other reserves is the special reserve of \$157m, arising on the redenomination of share capital. Of the remaining balance on other reserves, \$422m is distributable.

## Reconciliation of Movements in Shareholders' Funds

	Six months to 30 June 2000 \$m	Year Ended 31 Dec 1999 \$m
Net profit for the financial period	1,058	1,889
Dividends	-	(1,609)
	1,058	280
Other recognised gains and losses relating to the period/year	(2,042)	32,918
Issues of AstraZeneca Ordinary Shares	11	356
Repurchase of AstraZeneca Ordinary Shares	(353)	(183)
Net (reduction in) addition to shareholders' funds	(1,326)	33,371
Shareholders' funds at beginning of period/year	36,257	2,886
Shareholders' fund at end of period/year	34,931	36,257